Literature DB >> 25439433

Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration.

Eiko K de Jong1, Myrte B Breukink1, Rosa L Schellevis1, Bjorn Bakker1, Jacqueline K Mohr1, Sascha Fauser2, Jan E E Keunen1, Carel B Hoyng1, Anneke I den Hollander3, Camiel J F Boon4.   

Abstract

PURPOSE: In this study, single nucleotide polymorphisms (SNPs) at 19 loci, previously associated with age-related macular degeneration (AMD), were systematically tested for association in patients with chronic central serous chorioretinopathy (cCSC). In addition, we evaluated the effect of detailed phenotyping on these genetic associations.
DESIGN: Case-control study. PARTICIPANTS: We included 292 cCSC patients, 1147 AMD patients, and 1311 control individuals.
METHODS: We genotyped SNPs at 19 AMD-associated loci and 6 additional SNPs at the complement factor H (CFH) locus. Phenotyping of all patients was based on fundoscopy, spectral-domain optical coherence tomography, fluorescein angiography (FA), and indocyanine green angiography. MAIN OUTCOME MEASURES: We measured the allele frequencies of 25 AMD-associated SNPs and CFH haplotype frequencies in patients with cCSC and the effect of phenotypic subdivision of cCSC on genetic associations.
RESULTS: One SNP in ARMS2 (rs10490924) was significant after Bonferroni correction (Punadjusted=0.002; odds ratio [OR]=0.64). The SNPs at 3 other AMD loci (CFH, TNFRSF10A, ADAMTS9) showed a trend toward association with typical cCSC. Further analysis of the CFH locus identified 2 SNPs that significantly conferred increased risk for cCSC and 1 that was protective. The CFH-H3 haplotype was also found to be protective (P=0.01; OR=0.54). Using multimodal imaging, 197 patients were classified as having typical cCSC, 52 patients had unilateral abnormalities on FA that were otherwise typical of cCSC, and 43 patients had a clinical picture that could be compatible with cCSC, but with features that could also indicate other macular diseases. Significant differences of the minor allele frequencies of the tested SNPs were observed between these 3 phenotypic subgroups.
CONCLUSIONS: Chronic CSC is associated with genetic variants in ARMS2 and CFH, indicating a genetic and pathophysiologic overlap between cCSC and AMD. Intriguingly, alleles in ARMS2 and CFH that confer risk of AMD may be protective for cCSC, and alleles in CFH that are protective for AMD confer risk for cCSC. Significant differences in allele frequencies were found among the phenotypic subgroups for several SNPs, illustrating the importance of correct clinical classification.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25439433     DOI: 10.1016/j.ophtha.2014.09.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  42 in total

1.  Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy.

Authors:  Dandan Linghu; Hui Xu; Zhiqiao Liang; Tingting Gao; Zhaojun Lin; Xiaoxin Li; Lvzhen Huang; Mingwei Zhao
Journal:  Int Ophthalmol       Date:  2020-01-10       Impact factor: 2.031

Review 2.  Risk factors and biomarkers of age-related macular degeneration.

Authors:  Nathan G Lambert; Hanan ElShelmani; Malkit K Singh; Fiona C Mansergh; Michael A Wride; Maximilian Padilla; David Keegan; Ruth E Hogg; Balamurali K Ambati
Journal:  Prog Retin Eye Res       Date:  2016-05-06       Impact factor: 21.198

Review 3.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

4.  Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy.

Authors:  Elon H C van Dijk; Rosa L Schellevis; Maaike G J M van Bergen; Myrte B Breukink; Lebriz Altay; Paula Scholz; Sascha Fauser; Onno C Meijer; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong
Journal:  JAMA Ophthalmol       Date:  2017-05-01       Impact factor: 7.389

5.  [Uniform classification of the pachychoroid spectrum disorders].

Authors:  Alaa Din Abdin; Shady Suffo; Fabian N Fries; Hakan Kaymak; Berthold Seitz
Journal:  Ophthalmologe       Date:  2021-04-26       Impact factor: 1.059

6.  Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study.

Authors:  Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Lebriz Altay; Bjorn Bakker; Bobby P C Koeleman; Lambertus A Kiemeney; Dorine W Swinkels; Jan E E Keunen; Sascha Fauser; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon; Eiko K de Jong
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

7.  Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.

Authors:  Bertan Cakir; Franziska Fischer; Christoph Ehlken; Anima Bühler; Andreas Stahl; Günther Schlunck; Daniel Böhringer; Hansjürgen Agostini; Clemens Lange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-05       Impact factor: 3.117

8.  CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Alexandre Matet; Suzanne Yzer; Emily Y Chew; Alejandra Daruich; Francine Behar-Cohen; Richard F Spaide
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

Review 9.  [Central serous chorioretinopathy].

Authors:  Laurenz Pauleikhoff; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmologe       Date:  2021-04-16       Impact factor: 1.059

10.  Association of central serous chorioretinopathy with single nucleotide polymorphisms in complement factor H gene in Iranian population.

Authors:  Reza Karkhaneh; Mohsen Toufighi; Akbar Amirfiroozy; Aliasghar Ahmad-Raji; Oveis Ahmadzadeh; Alborz Mahdavi; Morteza Naderan
Journal:  Eye (Lond)       Date:  2021-05-11       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.